We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Daewoong Pharmaceutical

News List

Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment prnasia
September 30, 2020
Daewoong Pharmaceutical (Daewoong) (CEO Sengho Jeon) announced the result of its phase 2 clinical trial on enavogliflozin, SGLT2 inhibitor for diabetes currently in the process of development, for the first time at the ...
Daewoong finds niclosamide effective against Covid-19 in animal tests pharmaceutical-technology
June 11, 2020
South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal tests.
Daewoong Pharmaceutical introduced the excellence of NABOTA® (Prabotulinumtoxin A) biospectrumasia
July 09, 2019
Botulinum toxin drug product manufactured by Daewoong proved efficacy and safety through FDA approval based on its non-inferiority results to Botox and stability in large-scale global clinical trials
Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate pharmafocusasia
December 19, 2018
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with ....